ERASCA INC. - COMMON STOCK

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

27 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

14 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 08:00:00 提供 Nasdaq GlobeNewswire

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

11 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

09 11 2023 16:01:00 提供 Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences in November

08 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Erasca to Present at the Cantor Global Healthcare Conference

19 9 2023 08:00:01 提供 Nasdaq GlobeNewswire

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

05 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

29 8 2023 08:00:00 提供 Nasdaq GlobeNewswire

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

10 8 2023 16:01:00 提供 Nasdaq GlobeNewswire

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

22 6 2023 16:01:00 提供 Nasdaq GlobeNewswire

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

05 6 2023 16:01:00 提供 Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences

01 6 2023 08:00:00 提供 Nasdaq GlobeNewswire

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

31 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

25 5 2023 17:00:00 提供 Nasdaq GlobeNewswire

Erasca Further Strengthens Business Leadership with Two Key Promotions

16 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

Erasca Reports First Quarter 2023 Financial Results and Business Updates

15 5 2023 16:01:00 提供 Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

02 5 2023 08:00:02 提供 Nasdaq GlobeNewswire

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

01 5 2023 08:00:00 提供 Nasdaq GlobeNewswire